Company Announcements

Beckley Psytech to present at H.C. Wainwright 2nd Annual Psychedelics Conference and Stifel 2nd An...

Company Announcements

Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resista...

Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements

Company Announcements

Beckley Psytech to attend 11th Annual LifeSci Partners Virtual Corporate Access Event

CEO to participate in a panel discussion on the topic of “Psychedelics: More Than Just a Trip” – January 5, 2022 at 10:00 am ET / 3:00 pm GMT

Company Announcements

Beckley Psytech announces first cohort dosed in Phase 1 clinical trial assessing safety and tolerabi...

Press release

Company Announcements

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic ...

Company Announcements

Beckley Psytech to present at Jefferies 2021 London Healthcare Conference

Cosmo Feilding Mellen, Chief Executive Officer, will present at the Jefferies 2021 London Healthcare Conference, taking place in-person and virtually from 16th to 19th November, 2021.

Company Announcements

Beckley Psytech announces first patient has received low-dose psilocybin in world-first clinical tri...

Press Release

Company Announcements

Dr Frank Wiegand, experienced neuroscience leader joins Beckley Psytech as Chief Medical Officer

Company Announcements

Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

Company Announcements

Beckley Psytech partners with Fluence to create psychedelic therapy training programme